Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Thyroid Carcinoma, Anaplastic 1Sarcoma 1Nonseminomatous germ cell tumor 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Hairy Cell 1Glioma 1Gastrointestinal Stromal Tumors 1Biliary Tract Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1trametinib 1regorafenib 1milademetan 1larotrectinib 1futibatinib 1dabrafenib 1brigimadlin 1apixaban 1TAS-116 1Rivaroxaban 1Ramucirumab 1Poly(ADP-ribose) Polymerase Inhibitors 1Nivolumab 1Gemcitabine 1Fluorouracil 1Dalteparin 1Clinical Trials, Phase II as Topic 1Cisplatin 1Carboplatin 1Bevacizumab 14-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × dabrafenib × Sarcoma × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡